Cargando…

What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015–2020)

OBJECTIVE: To examine factors associated with accrual rate in industry sponsored clinical trials supporting US Food and Drug Administration (FDA) cancer drug approvals from 2015 to 2020. DESIGN, SETTING AND PARTICIPANTS: Retrospective cross-sectional study included 194 pivotal trials supporting canc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jenei, Kristina, Haslam, Alyson, Olivier, Timothée, Miljkovíc, Milos, Prasad, Vinay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558788/ https://www.ncbi.nlm.nih.gov/pubmed/36207035 http://dx.doi.org/10.1136/bmjopen-2022-064458

Ejemplares similares

Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020
por: Olivier, Timothée, et al.
Publicado: (2023)

Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020
por: Miljković, Miloš D., et al.
Publicado: (2022)

Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action
por: Olivier, Timothée, et al.
Publicado: (2021)

FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
por: Chen, Emerson Y., et al.
Publicado: (2020)

Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020
por: Haslam, Alyson, et al.
Publicado: (2021)

FDA limits authorised use of Janssen COVID-19 vaccine
Publicado: (2022)

How Often do Medical Specialties Question the Practices that They Perform? An Empirical, Cross-Sectional Analysis of the Published Literature
por: Haslam, Alyson, et al.
Publicado: (2022)

Accrual, Publication Bias, and the Coronavirus in 2020
por: Bates, Susan E.
Publicado: (2020)

Reporting of Physicians’ or Investigators’ Choice of Treatment in Oncology Randomized Clinical Trials
por: Olivier, Timothée, et al.
Publicado: (2022)

Sotorasib in KRAS(G12C) mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival?
por: Olivier, Timothée, et al.
Publicado: (2022)

Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer
por: Olivier, Timothée, et al.
Publicado: (2023)

The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.
por: Olivier, Timothée, et al.
Publicado: (2022)

Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers
por: Haslam, Alyson, et al.
Publicado: (2023)

Eligibility for Human Leukocyte Antigen–Based Therapeutics by Race and Ethnicity
por: Olivier, Timothée, et al.
Publicado: (2023)

Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis
por: Ivama-Brummell, Adriana M., et al.
Publicado: (2023)

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
por: Haslam, Alyson, et al.
Publicado: (2019)

Characteristics of Facebook’s third-party medical fact checkers
por: Haslam, Alyson, et al.
Publicado: (2022)

Comparability of Control and Comparison Groups in Studies Assessing Long COVID
por: Haslam, Alyson, et al.
Publicado: (2023)

A Disability Bioethics Reading of the FDA and EMA Evaluations on the Marketing Authorisation of Growth Hormone for Idiopathic Short Stature Children
por: Murano, Maria Cristina
Publicado: (2020)

GANIL authorised
Publicado: (1975)

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs
por: Haslam, Alyson, et al.
Publicado: (2020)

Medical Reversals in Family Practice: A Review
por: Haslam, Alyson, et al.
Publicado: (2020)

The frequency of assessment of progression in randomized oncology clinical trials
por: Haslam, Alyson, et al.
Publicado: (2021)

Scoping Review of Published Oncology Meta-analyses in High-Impact Oncology Journals
por: Haslam, Alyson, et al.
Publicado: (2023)

The effect of gastrointestinal microbiome supplementation on immune checkpoint inhibitor immunotherapy: a systematic review
por: Bhatt, Anjali, et al.
Publicado: (2023)

Accrual monitoring in cardiovascular trials
por: Baldi, Ileana, et al.
Publicado: (2017)

Cross-sectional analysis characterizing the use of rank preserving structural failure time in oncology studies: changes to hazard ratio and frequency of inappropriate use
por: Prasad, Vinay, et al.
Publicado: (2023)

Low-Overhead Accrual Failure Detector
por: Ren, Xiao, et al.
Publicado: (2012)

Clinical Trial Accrual: Obstacles and Opportunities
por: Rimel, B. J.
Publicado: (2016)

CostPlus and implications for generic imatinib
por: Jenei, Kristina, et al.
Publicado: (2022)

Association of Adjuvant or Metastatic Setting With Discontinuation of Cancer Drugs in Clinical Trials
por: Ahmed, Nibras, et al.
Publicado: (2022)

Frequency and Characteristics of Trials Using Medical Writer Support in High-Impact Oncology Journals
por: Buck, Eva, et al.
Publicado: (2023)

Multiple myeloma: challenges with deciding the optimal sequencing strategy
por: Walia, Anushka, et al.
Publicado: (2023)

TRLS-01. FDA ANALYSIS OF EXPANDED ACCESS USE IN PEDIATRIC PATIENTS WITH CNS TUMORS FROM 2015 TO 2020
por: Duke, Elizabeth, et al.
Publicado: (2023)

Early termination of cardiovascular trials as a consequence of poor accrual: analysis of ClinicalTrials.gov 2006–2015
por: Baldi, Ileana, et al.
Publicado: (2017)

2020 FDA TIDES (Peptides and Oligonucleotides) Harvest
por: Al Musaimi, Othman, et al.
Publicado: (2021)

Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials
por: Haslam, Alyson, et al.
Publicado: (2020)

Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
por: Benjamin, David J., et al.
Publicado: (2022)

Clinical Trials Portfolio and Regulatory History of Idelalisib in Indolent Non-Hodgkin Lymphoma: A Systematic Review and Meta-analysis
por: Banerjee, Titas, et al.
Publicado: (2023)

Authorisation for work with electrical equipment
por: Balle, Christoph
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_rq0fl6qin4gdqs1b97g1ce47dj